RecruitingPhase 1NCT05783622
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janux Therapeutics
- Principal Investigator
- Janux Therapeutics, MDJanux Therapeutics
- Intervention
- JANX008(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2023 – 2027
Study locations (18)
- City of Hope Medical Center, Duarte, California, United States
- University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of California San Diego Moores Cancer Center, San Diego, California, United States
- Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Laura and Isaac Perlmutter Cancer Center NYU Langone Health, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- The Christ Hospital Cancer Center, Cincinnati, Ohio, United States
- Ohio State University Hospital, Columbus, Ohio, United States
- University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05783622 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital